The Hong Kong Stock Exchange's latest data shows that on October 23, 26, and 27, Chairman Liu Yanjun acquired a combined 263,300 shares of BAO PHARMA-B (02659), with a total consideration of approximately HK$2.0243 million.
Following the purchases, his latest holdings stand at approximately 26.4702 million shares, representing a latest shareholding ratio of 17.15%.
The transaction also involves another connected party: Wang Zheng.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments